#United States #Menlo Park #Endovascular Engineering #ENGULF Study #Hēlo Platform

Endovascular Engineering's Promising Studies at SIR and SCAI 2026

Endovascular Engineering, Inc. (E2), known for its innovative solutions in the treatment of venous thromboembolism (VTE), has recently made headlines by announcing the acceptance of two pivotal abstracts. Set to be presented at the upcoming Society of Interventional Radiology (SIR) Annual Scientific Meeting and the Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions, both taking place in April 2026, these findings center around their ongoing ENGULF study and the Hēlo® Platform.

The significance of these presentations cannot be overstated. Both are classified as late-breaking, a designation reserved for the most impactful research at these conferences. This classification highlights E2's commitment to advancing medical practice through evidence-based innovation. The Hēlo® Platform is specifically designed for treating pulmonary embolism and facilitating the removal of clots from peripheral veins, addressing a critical patient need.

Background on the ENGULF Study

The ENGULF study is a prospective investigatory trial evaluating the safety and efficacy of the Hēlo Thrombectomy System in treating pulmonary embolism. Previous findings from this study already indicated low adverse event rates, alongside significant reductions in the right ventricular to left ventricular (RV/LV) ratio, showcasing the system's single-pass treatment strategy as effective.

The anticipation surrounding E2's presentations builds on the momentum generated during their late-breaking presentation at the VIVA 2025 conference in Las Vegas, where initial outcomes of the ENGULF study were first unveiled. Now, at SIR and SCAI, E2 intends to showcase comprehensive datasets that provide deeper insights into the efficacy and safety of their thrombectomy solutions.

Presentation Highlights: SIR

Dr. Julie C. Bulman, the ENGULF National Co-Principal Investigator from Beth Israel Deaconess Medical Center, will present findings regarding the quality of blood return during mechanical thrombectomy procedures targeting pulmonary embolism. This is a crucial area of inquiry, as historical data have largely relied on extrapolations from trauma studies and non-human models, which might not accurately reflect thrombolysis in clinical scenarios.

Dr. Bulman emphasizes that, "Rigorous evaluation of blood quality is essential to understanding how blood return can be thoughtfully integrated into PE intervention." Her findings, which include laboratory testing combined with prospective clinical data, will establish a significant scientific basis for understanding blood return in the context of thrombectomy.

Presentation Highlights: SCAI

At SCAI, Dr. Andrew J. Klein, ENGULF National Co-Principal Investigator at Piedmont Hospital in Atlanta, will expand on the complete ENGULF dataset. His presentation aims to compare outcomes between patients treated with and without blood return methodologies, illuminating procedural nuances and their impact on patient outcomes.

Dr. Klein notes, "The complete ENGULF dataset provides physicians with insight into how procedural strategy impacts outcomes in patients with pulmonary embolism." By presenting this comparative analysis within a single prospectively tracked trial, significant differences in safety, efficiency, and clinical effectiveness can be identified, which is invaluable for informing medical practice.

Looking Ahead

E2's Chief Executive Officer, Dan Rose, commented on the forthcoming presentations, stating, "Both late-breaking presentations at SIR and SCAI demonstrate the depth and rigor of the clinical evidence supporting the Hēlo® Platform." This advancement showcases the increasing interest from the clinical community in enhancing treatment for pulmonary embolism and highlights the importance of innovative solutions grounded in clinical science.

E2 acknowledges the contributions of patients involved in the ENGULF study, as well as the dedication of the physicians and hospital partners who collaborate to advance clinical evidence in thrombectomy.

As Endovascular Engineering continues to pioneer solutions in the VTE treatment landscape, it stands ready to redefine intervention approaches that prioritize patient outcomes and safety. The upcoming presentations at the SIR and SCAI conferences signify a critical milestone in this journey, paving the way for innovative therapeutic options in acute thrombotic scenarios.

For more information on the Hēlo™ Thrombectomy System and ongoing research, E2 encourages interested parties to visit their official website and follow their updates on LinkedIn.